Merck KGaA to triple its ADC manufacturing capacity in St. Louis
The German science and technology group Merck KGaA has announced a € 70 million expansion of its antibody-drug conjugates (ADC) manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment will triple existing capacity and enhance the CDMO offering. With additional capacity and by scaling utilities and enhancing Process and Analytical Development (PAD) labs, Merck KGaA will provide industry-leading support for early-stage and commercial bioconjugates. The company’s goal is to ensure clients can bring their innovations to market more effectively and with shorter turnaround times.
The ADC capacity expansion project will:
• Upgrade 3200 m2 to benefit the Process and Analytical Development, Quality Control, Research and Development, Manufacturing, and Logistics departments.
• Add new labs, a dedicated manufacturing buffer preparation facility, and a cold storage and a GMP-controlled room temperature warehouse that will be located close to the existing facility.
Building on its reputation as the first commercially approved ADC CDMO in North America, the Life Science business of Merck KGaA has made significant investments to expand its ADC manufacturing capabilities for clients worldwide. In 2022, the company opened its € 59 million, 6500 m2 facility in Verona, Wisconsin, USA, dedicated to doubling the production of the most highly potent active pharmaceutical ingredients (HPAPIs) used in novel cancer therapies, including ADCs. Recently, the company has also launched Mobius ® ADC Reactor, a scalable single-use mixer specifically designed for ADC manufacturing and ChetoSensar®, a technology that alleviates ADC solubility challenges, as well as the ADCore portfolio of advanced payload intermediates.
29/10/2024
Merck KGaA to triple its ADC manufacturing capacity in St. Louis
Merck KGaA to triple its ADC manufacturing capacity in St. Louis
The German science and technology group Merck KGaA has announced a € 70 million expansion of its antibody-drug conjugates (ADC) manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment will triple existing capacity and enhance the CDMO offering. With additional capacity and by scaling utilities and enhancing Process and Analytical Development (PAD) labs, Merck KGaA will provide industry-leading support for early-stage and commercial bioconjugates. The company’s goal is to ensure clients can bring their innovations to market more effectively and with shorter turnaround times.
The ADC capacity expansion project will:
• Upgrade 3200 m2 to benefit the Process and Analytical Development, Quality Control, Research and Development, Manufacturing, and Logistics departments.
• Add new labs, a dedicated manufacturing buffer preparation facility, and a cold storage and a GMP-controlled room temperature warehouse that will be located close to the existing facility.
Building on its reputation as the first commercially approved ADC CDMO in North America, the Life Science business of Merck KGaA has made significant investments to expand its ADC manufacturing capabilities for clients worldwide. In 2022, the company opened its € 59 million, 6500 m2 facility in Verona, Wisconsin, USA, dedicated to doubling the production of the most highly potent active pharmaceutical ingredients (HPAPIs) used in novel cancer therapies, including ADCs. Recently, the company has also launched Mobius ® ADC Reactor, a scalable single-use mixer specifically designed for ADC manufacturing and ChetoSensar®, a technology that alleviates ADC solubility challenges, as well as the ADCore portfolio of advanced payload intermediates.
29/10/2024
COMMENTS ARE OFF THIS POST